For research use only. Not for therapeutic Use.
Doxofylline-d6 (CAS: 1219805-99-8), a premium pharmaceutical research compound designed for advanced studies in respiratory and pulmonary research. As a deuterated analog of Doxofylline, it offers enhanced stability and improved pharmacokinetic properties. Doxofylline-d6 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for asthma and chronic obstructive pulmonary disease (COPD). Trusted by leading laboratories, Doxofylline-d6 is your go-to solution for cutting-edge respiratory research. Unlock new possibilities in asthma and COPD treatment with Doxofylline-d6, where innovation meets reliability.
| Catalog Number | S000147 |
| CAS Number | 1219805-99-8 |
| Molecular Formula | C11H8D6N4O4 |
| Purity | ≥95% |
| Target | Metabolic Enzyme/Protease |
| IUPAC Name | 7-(1,3-dioxolan-2-ylmethyl)-1,3-bis(trideuteriomethyl)purine-2,6-dione |
| InChI | InChI=1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3/i1D3,2D3 |
| InChIKey | HWXIGFIVGWUZAO-WFGJKAKNSA-N |
| SMILES | [2H]C([2H])([2H])N1C2=C(C(=O)N(C1=O)C([2H])([2H])[2H])N(C=N2)CC3OCCO3 |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Shukla D, et al. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2009 Oct;10(14):2343-56. |
